Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 3/20 | 0.41 |
| ▸ | RAB9A | P51151 | 3/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | SLC9A1 | P19634 | 3/20 | 0.40 |
| ▸ | HTR7 | P34969 | 3/20 | 0.38 |
| ▸ | HTR2B | P41595 | 3/20 | 0.38 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 1/20 | 0.37 |
| ▸ | CA2 | P00918 | 1/20 | 0.37 |
| ▸ | PARP1 | P09874 | 1/20 | 0.37 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.37 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.37 |
| ▸ | PARP4 | Q9UKK3 | 1/20 | 0.37 |
| ▸ | BACE1 | P56817 | 1/20 | 0.36 |
| ▸ | RARA | P10276 | 1/20 | 0.36 |
| ▸ | RARB | P10826 | 1/20 | 0.36 |
| ▸ | RARG | P13631 | 1/20 | 0.36 |
| ▸ | DRD2 | P14416 | 1/20 | 0.36 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12366401 | 0.89 | SLC9A1 (0.50) | NPC1RAB9ASLC9A1HTR7HTR2B | |
| SCHEMBL12366341 | 0.88 | SLC9A1 (0.41) | NPC1RAB9ASMN1; SMN2MAPTSLC9A1 | |
| SCHEMBL12366388 | 0.86 | HTR2B (0.40) | SLC9A1HTR7HTR2BDRD2ADRA1D | |
| SCHEMBL12366412 | 0.86 | SLC9A1 (0.40) | NPC1RAB9ASMN1; SMN2MAPTSLC9A1 | |
| SCHEMBL12366354 | 0.85 | HTR2B (0.44) | NPC1RAB9ASMN1; SMN2MAPTSLC9A1 | |
| SCHEMBL2259569 | 0.85 | SLC9A1 (0.41) | SLC9A1HTR7HTR2BDRD2ADRA1D | |
| SCHEMBL12366373 | 0.85 | HTR2B (0.45) | SLC9A1HTR7HTR2BDRD2ADRA1D | |
| SCHEMBL12366329 | 0.85 | HTR2B (0.47) | SLC9A1HTR7HTR2BDRD2ADRA1D | |
| SCHEMBL2263536 | 0.84 | HTR5A (0.39) | NPC1RAB9ASMN1; SMN2MAPTSLC9A1 | |
| SCHEMBL12365123 | 0.84 | RARA (0.47) | NPC1RAB9ASMN1; SMN2MAPTMAP4K4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110207729-A1 | BICYCLIC ACYLGUANIDINE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2011-08-25 | — | — | US | disclosed |
| US-20110207729-A1 | BICYCLIC ACYLGUANIDINE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2011-08-25 | — | — | US | disclosed |
| EP-2177505-A1 | BICYCLIC ACYLGUANIDINE DERIVATIVE | Astellas Pharma Inc. (JP) | 2010-04-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110207729-A1 | BICYCLIC ACYLGUANIDINE DERIVATIVE | HTR5A, HTR2A, HTR1E | NPC1 1519/4885RAB9A 430/4885SMN1; SMN2 3728/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.